Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
11. Januar 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision...
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
03. Januar 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision...
Vivos Inc. Provides Intellectual Property Protection Update
12. Mai 2022 09:30 ET
|
Vivos Inc.
Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed...
Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
24. Januar 2022 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc Initiates Isopet® Therapy in Horses
24. Juni 2021 09:30 ET
|
Vivos Inc.
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time
07. Dezember 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of...
Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors
03. September 2020 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
26. August 2020 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating...
Vivos Inc. Provides 2019 Recap and Outlines 2020 Objectives
13. Januar 2020 07:30 ET
|
Vivos Inc.
Richland WA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2019 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2020, I think it is...
Vivos Inc. Announces Listing to the OTCQB
18. September 2019 07:00 ET
|
Vivos Inc.
Richland WA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to...